These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22257609)

  • 41. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Management of refractory ITP with thrombopoietin receptor agonists].
    Tomiyama Y
    Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
    [No Abstract]   [Full Text] [Related]  

  • 43. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.
    Zimrin A; Chumsri S
    Ann Hematol; 2013 Aug; 92(8):1145-6. PubMed ID: 23328792
    [No Abstract]   [Full Text] [Related]  

  • 45. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
    Kurata Y
    Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
    [No Abstract]   [Full Text] [Related]  

  • 46. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
    Molineux G; Newland A
    Br J Haematol; 2010 Jul; 150(1):9-20. PubMed ID: 20298251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary immune thrombocytopenia in adults: clinical practice versus management guidelines.
    Ng T; Gatt A; Smith M
    Postgrad Med J; 2017 Nov; 93(1105):645-646. PubMed ID: 28720688
    [No Abstract]   [Full Text] [Related]  

  • 48. Idiopathic thrombocytopenic purpura: advances in management.
    Neunert C
    Clin Adv Hematol Oncol; 2011 May; 9(5):404-6. PubMed ID: 21685870
    [No Abstract]   [Full Text] [Related]  

  • 49. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
    Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
    Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current treatment options for primary immune thrombocytopenia.
    Salama A
    Expert Rev Hematol; 2011 Feb; 4(1):107-18. PubMed ID: 21322783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists.
    Lown R; Rhodes E; Bosworth J; Shannon MS; Stasi R
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):809-12. PubMed ID: 21326159
    [No Abstract]   [Full Text] [Related]  

  • 53. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.
    Altomare I; Wasser J; Pullarkat V
    Am J Hematol; 2012 Oct; 87(10):984-7. PubMed ID: 22729832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustaining platelet counts in chronic ITP.
    Nurden AT
    Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
    [No Abstract]   [Full Text] [Related]  

  • 55. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Immune thrombocytopenias: pathophysiology and treatment].
    Godeau B
    Bull Acad Natl Med; 2013 Feb; 197(2):407-17. PubMed ID: 24919370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thrombopoietin receptor agonists in the treatment of thrombocytopenia.
    Newland A
    Curr Opin Hematol; 2009 Sep; 16(5):357-64. PubMed ID: 19553811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombopoietin-receptor agonists.
    Basciano PA; Bussel JB
    Curr Opin Hematol; 2012 Sep; 19(5):392-8. PubMed ID: 22872157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.